GOVX GeoVax Labs, Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
14.80
P/S
4.09
EV/EBITDA
-0.12
DCF Value
$2,339,802.99
FCF Yield
-545.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
102.5%
Operating Margin
-2523.4%
Net Margin
-2507.3%
ROE
-0.0%
ROA
-716.5%
ROIC
-2421.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $0.00 | $-5.3M | $— |
| Q4 null | $0.00 | $-4.4M | $— |
| FY null | $2.5M | $-21.5M | $— |
| Q3 null | $0.00 | $-6.3M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$100.00
Target (Median)
$100.00
Target Range
$100.00 - $100.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.35
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.